Purpose To investigate outcomes after Brolucizumab injection in naive treatment or non-responder patients with exudative age-related macular degeneration (AMD).Methods It is a retrospective, comparative, cohort study conducted at the tertiary referral center of the University Hospital Polyclinic of Bari, for 5 years, from November 2017 until May 2022. 41 eyes with wet-AMD (w-AMD) were included, undergoing anti-vascular endothelial growth factor (VEGF) intravitreal injections. The sample was divided into two groups, the Bro-Switch group, and the Bro-Naive group. The Bro-Switch group previously received a slot of other anti-VEGF intravitreal drugs. The Bro-Naive group received Brolucizumab (Bro) as the first treatment. The pigment epithelium detachment (PED) and the best-corrected visual acuity (BCVA) outcomes before and after Bro-injection were evaluated.Results A significant reduction in PED measurement was registered in all eyes treated with Bro-injection (p = 0.35). The Bro-Naive group improved better in PED measurement (mean difference: 297.92 +/- 72,32) as compared to the Bro-Switch group (mean difference: 185.06 +/- 11.07). On the contrary, no significant reduction in BCVA in the two groups was recorded (p = 0.66).Conclusion We suggest Bro-injection for w-AMD as effective anatomical outcomes in PED flattening, but not similar in visual results. Although this study evaluated short-term outcomes, the hopeful results can lead to interesting medium-long time effects.
Brolucizumab effectiveness in pigment epithelium detachment due to exudative AMD in naïve treatment or non-responder patients
Reibaldi, Michele;
2024-01-01
Abstract
Purpose To investigate outcomes after Brolucizumab injection in naive treatment or non-responder patients with exudative age-related macular degeneration (AMD).Methods It is a retrospective, comparative, cohort study conducted at the tertiary referral center of the University Hospital Polyclinic of Bari, for 5 years, from November 2017 until May 2022. 41 eyes with wet-AMD (w-AMD) were included, undergoing anti-vascular endothelial growth factor (VEGF) intravitreal injections. The sample was divided into two groups, the Bro-Switch group, and the Bro-Naive group. The Bro-Switch group previously received a slot of other anti-VEGF intravitreal drugs. The Bro-Naive group received Brolucizumab (Bro) as the first treatment. The pigment epithelium detachment (PED) and the best-corrected visual acuity (BCVA) outcomes before and after Bro-injection were evaluated.Results A significant reduction in PED measurement was registered in all eyes treated with Bro-injection (p = 0.35). The Bro-Naive group improved better in PED measurement (mean difference: 297.92 +/- 72,32) as compared to the Bro-Switch group (mean difference: 185.06 +/- 11.07). On the contrary, no significant reduction in BCVA in the two groups was recorded (p = 0.66).Conclusion We suggest Bro-injection for w-AMD as effective anatomical outcomes in PED flattening, but not similar in visual results. Although this study evaluated short-term outcomes, the hopeful results can lead to interesting medium-long time effects.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
